Study links Pfizer's Premarin to blood clot risk


Pfizer's (PFE) blockbuster menopause drug Premarin may increase the risk of blood clots compared to estradiol, new research suggests.

Although the results will need to be replicated in order to draw any definitive conclusions, it could be that oral estrogens aren't created equal in terms of safety, the study's lead author tells Bloomberg.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs